Nov. 2, 2013-- Gilead Sciences, Inc. today announced results from a Phase 3 study, PHOTON-1, evaluating the investigational once-daily nucleotide analogue sofosbuvir for the treatment of chronic hepatitis C virus infection among patients co-infected with HIV.
http://www.drugs.com/clinical_trials/gilead-announces-phase-3-results-all-oral-sofosbuvir-16296.html?
http://www.drugs.com/clinical_trials/gilead-announces-phase-3-results-all-oral-sofosbuvir-16296.html?
No comments:
Post a Comment